1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Bader, R.
Zerbe, O.
Beck-Sickinger, A.G.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C4 H9 N O2
103.120
n
ALPHA-AMINOISOBUTYRIC ACID
L-peptide linking
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
H2 N
16.023
AMINO GROUP
non-polymer
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
US
J.Biol.Chem.
JBCHA3
0071
0021-9258
275
36043
36048
10.1074/jbc.M000626200
10944518
The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats.
2000
10.2210/pdb1fvn/pdb
pdb_00001fvn
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
4200.611
NEUROPEPTIDE Y
I31A, T32(AIB)
1
syn
polymer
no
yes
YPSKPDNPGEDAPAEDLARYYSALRHYINLA(AIB)RQRY(NH2)
YPSKPDNPGEDAPAEDLARYYSALRHYINLAARQRYX
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
database_2
pdbx_nmr_software
pdbx_nmr_spectrometer
pdbx_struct_assembly
pdbx_struct_oper_list
struct_conn
struct_ref_seq_dif
struct_site
repository
Initial release
Version format compliance
Version format compliance
Data collection
Database references
Derived calculations
1
0
2000-10-04
1
1
2008-04-27
1
2
2011-07-13
1
3
2021-11-03
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_nmr_software.name
_pdbx_nmr_spectrometer.model
_struct_conn.pdbx_leaving_atom_flag
_struct_ref_seq_dif.details
_struct_site.pdbx_auth_asym_id
_struct_site.pdbx_auth_comp_id
_struct_site.pdbx_auth_seq_id
Solution structure of human Neuropeptide Y
RCSB
Y
RCSB
2000-09-20
REL
REL
The peptide was a designed synthetic molecule. The sequence of the peptide is derived from NPY naturally found in Sus scrofa (pig).
sample
This structure was determined using standard 2D homonuclear techniques using 200ms NOESY mixing time
structures with the lowest energy
100
30
2D NOESY
E-COSY
2D NOESY
0
3.1
1
atm
310
K
0
3.1
1
atm
310
K
0
3.1
1
atm
310
K
torsion angle dynamics
1
lowest energy
2mM
90% H2O/10% D2O
4mM
90% H2O/10% D2O
2mM
100% D2O
Bruker
processing
XwinNMR
2.1
Bartels & Wuthrich
data analysis
XEASY
1.53
Guntert & Wuthrich
structure solution
DYANA
1.5
Guntert & Wuthrich
refinement
DYANA
1.5
600
Bruker
AVANCE
TYR
1
n
1
TYR
1
A
PRO
2
n
2
PRO
2
A
SER
3
n
3
SER
3
A
LYS
4
n
4
LYS
4
A
PRO
5
n
5
PRO
5
A
ASP
6
n
6
ASP
6
A
ASN
7
n
7
ASN
7
A
PRO
8
n
8
PRO
8
A
GLY
9
n
9
GLY
9
A
GLU
10
n
10
GLU
10
A
ASP
11
n
11
ASP
11
A
ALA
12
n
12
ALA
12
A
PRO
13
n
13
PRO
13
A
ALA
14
n
14
ALA
14
A
GLU
15
n
15
GLU
15
A
ASP
16
n
16
ASP
16
A
LEU
17
n
17
LEU
17
A
ALA
18
n
18
ALA
18
A
ARG
19
n
19
ARG
19
A
TYR
20
n
20
TYR
20
A
TYR
21
n
21
TYR
21
A
SER
22
n
22
SER
22
A
ALA
23
n
23
ALA
23
A
LEU
24
n
24
LEU
24
A
ARG
25
n
25
ARG
25
A
HIS
26
n
26
HIS
26
A
TYR
27
n
27
TYR
27
A
ILE
28
n
28
ILE
28
A
ASN
29
n
29
ASN
29
A
LEU
30
n
30
LEU
30
A
ALA
31
n
31
ALA
31
A
AIB
32
n
32
AIB
32
A
ARG
33
n
33
ARG
33
A
GLN
34
n
34
GLN
34
A
ARG
35
n
35
ARG
35
A
TYR
36
n
36
TYR
36
A
NH2
237
n
37
NH2
37
A
author_defined_assembly
1
monomeric
A
AIB
32
ALPHA-AMINOISOBUTYRIC ACID
A
AIB
32
ALA
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
A
O
H
ILE
ALA
28
31
1.54
3
A
A
O
H
ILE
ALA
28
31
1.54
4
A
A
O
H
ILE
ALA
28
31
1.52
5
A
A
O
H
ILE
ALA
28
31
1.56
7
A
A
O
H
ILE
ALA
28
31
1.55
7
A
A
O
H
ALA
SER
18
22
1.58
8
A
A
O
H
ARG
TYR
33
36
1.56
12
A
A
O
H
ARG
TYR
33
36
1.52
13
A
A
O
H
ILE
ALA
28
31
1.56
14
A
A
O
H
ILE
ALA
28
31
1.56
15
A
A
O
HN1
ARG
NH2
33
37
1.55
15
A
A
O
H
AIB
ARG
32
35
1.56
18
A
A
O
H
ILE
ALA
28
31
1.55
18
A
A
O
H
ARG
TYR
33
36
1.60
20
A
A
O
H
ILE
ALA
28
31
1.53
23
A
A
O
H
ILE
ALA
28
31
1.59
24
A
A
O
H
ILE
ALA
28
31
1.53
25
A
A
O
H
ILE
ALA
28
31
1.59
26
A
A
O
H
ALA
SER
18
22
1.59
29
A
A
O
H
ALA
SER
18
22
1.58
30
A
A
O
H
ALA
SER
18
22
1.59
1
A
SER
3
63.72
76.23
1
A
ASP
6
50.18
95.29
1
A
PRO
8
-74.95
-168.44
1
A
ASP
11
172.87
115.76
1
A
ALA
12
178.45
158.07
1
A
ALA
14
83.59
-51.58
1
A
ALA
31
-171.20
105.76
1
A
AIB
32
-154.47
-38.13
2
A
ASP
6
173.59
128.14
2
A
ASP
11
53.13
99.21
2
A
ALA
14
83.49
-51.58
2
A
ARG
33
-146.77
-46.15
3
A
SER
3
-67.79
70.11
3
A
LYS
4
62.84
142.31
3
A
GLU
10
68.30
72.23
3
A
ALA
31
-169.95
100.05
3
A
AIB
32
-149.94
-37.41
4
A
LYS
4
56.16
93.65
4
A
ASN
7
169.52
146.76
4
A
ASP
11
-141.03
-54.20
4
A
PRO
13
-74.97
-168.79
4
A
ALA
14
42.62
26.30
4
A
ALA
31
-163.77
99.80
4
A
AIB
32
-168.67
-33.17
5
A
LYS
4
67.80
93.62
5
A
ASP
6
65.32
125.81
5
A
ASN
7
178.25
150.83
5
A
ALA
12
66.75
69.34
5
A
GLU
15
-135.05
-34.65
5
A
AIB
32
-157.99
-39.16
6
A
SER
3
53.51
174.53
6
A
ASP
6
55.20
170.93
6
A
ASN
7
-40.46
100.71
6
A
GLU
10
69.73
65.91
6
A
ASP
11
-132.24
-50.41
6
A
ALA
12
71.22
67.62
6
A
ALA
31
-97.26
37.76
7
A
SER
3
63.58
151.73
7
A
ASP
6
76.66
118.16
7
A
ALA
12
-168.45
75.93
7
A
AIB
32
-159.70
-39.63
8
A
PRO
2
-75.03
-80.89
8
A
SER
3
61.52
110.46
8
A
ASP
6
163.59
-35.10
8
A
GLU
10
-130.10
-44.40
8
A
ALA
12
66.85
154.33
8
A
ALA
14
42.53
26.28
8
A
ALA
31
-79.49
-96.31
8
A
AIB
32
81.43
-25.83
9
A
ALA
12
66.59
86.78
9
A
ARG
33
-130.61
-42.85
10
A
ASP
6
70.17
90.68
10
A
ALA
31
-93.78
52.95
10
A
ARG
33
-141.69
-46.12
11
A
ASP
6
59.72
166.28
11
A
ASN
7
41.47
87.86
11
A
GLU
10
-104.71
59.16
11
A
ASP
11
43.46
84.05
11
A
ALA
12
179.13
73.96
12
A
ASP
6
59.57
91.96
12
A
ASP
11
178.38
161.38
12
A
ALA
14
84.05
-50.66
12
A
ALA
31
-94.86
49.73
13
A
LYS
4
-162.84
93.72
13
A
ASP
6
63.94
140.36
13
A
ALA
31
-93.41
42.60
14
A
SER
3
-165.83
76.01
14
A
PRO
5
-75.03
-163.77
14
A
ALA
14
83.65
-51.45
14
A
ALA
31
-108.64
61.55
15
A
SER
3
179.38
-70.87
15
A
LYS
4
72.80
157.51
15
A
ASN
7
172.95
160.68
15
A
GLU
10
39.25
84.57
15
A
ASP
11
49.37
94.81
15
A
ALA
31
-103.08
51.98
16
A
LYS
4
62.84
154.88
16
A
ALA
12
169.82
161.90
16
A
ALA
14
83.86
-51.19
16
A
ALA
31
-90.20
50.77
17
A
LYS
4
68.63
93.52
17
A
ASN
7
-40.46
100.74
17
A
GLU
10
-90.95
56.49
17
A
ASP
11
-134.63
-56.04
17
A
ALA
12
177.56
154.31
17
A
ALA
14
83.70
-51.34
17
A
ARG
35
-93.98
30.39
18
A
ASP
6
62.07
118.75
18
A
ASN
7
162.73
-51.99
18
A
ASP
11
57.56
106.60
18
A
ALA
14
83.89
-50.93
18
A
ALA
31
-79.75
-139.52
18
A
AIB
32
83.16
-22.98
19
A
PRO
2
-74.98
-88.89
19
A
SER
3
39.86
80.32
19
A
ASN
7
52.40
94.98
19
A
ALA
14
83.62
-51.41
20
A
SER
3
-147.05
-58.55
20
A
LYS
4
40.56
89.30
20
A
ASP
6
59.78
158.28
20
A
ASN
7
-174.63
132.64
20
A
ASP
11
179.04
87.83
20
A
PRO
13
-75.01
-169.72
20
A
ALA
14
42.58
26.34
20
A
ALA
31
-62.25
-97.71
20
A
ARG
33
-151.39
-50.33
20
A
ARG
35
-99.90
32.72
21
A
SER
3
50.94
-164.33
21
A
ASP
11
54.97
171.08
21
A
ALA
12
-37.71
98.29
21
A
ALA
14
176.07
-40.94
21
A
ALA
31
-111.90
54.57
21
A
ARG
33
-37.87
-31.29
22
A
SER
3
177.93
46.02
22
A
ASP
11
-45.92
109.87
23
A
SER
3
-174.67
-41.18
23
A
LYS
4
165.12
-53.35
23
A
ASP
6
-177.08
-56.51
23
A
ASN
7
41.85
88.87
23
A
ALA
12
-37.66
98.31
23
A
ALA
14
176.09
-40.97
23
A
AIB
32
-160.16
21.59
23
A
ARG
33
-159.92
-45.30
24
A
SER
3
74.42
-60.33
24
A
ALA
12
-172.72
72.84
24
A
ALA
14
176.33
-38.10
24
A
ALA
31
-55.49
-97.90
24
A
AIB
32
73.26
-1.09
25
A
SER
3
176.71
86.73
25
A
PRO
5
-75.00
-167.17
25
A
ASP
6
-168.01
111.86
25
A
GLU
10
-176.10
67.23
25
A
ASP
11
67.45
97.16
25
A
ALA
14
83.64
-51.41
25
A
ARG
33
-134.54
-44.93
25
A
ARG
35
-91.27
31.61
26
A
LYS
4
53.05
88.84
26
A
ALA
12
-157.10
84.97
26
A
ALA
31
-85.31
-97.26
26
A
AIB
32
82.16
-27.38
26
A
GLN
34
-38.75
-29.58
26
A
ARG
35
-113.46
58.79
27
A
SER
3
-154.60
84.58
27
A
LYS
4
56.60
88.96
27
A
ASN
7
62.58
132.67
27
A
GLU
10
37.50
90.42
27
A
ASP
11
174.80
92.66
27
A
ALA
31
-106.91
50.76
27
A
ARG
33
-141.10
-45.57
27
A
ARG
35
-91.07
30.24
28
A
SER
3
-152.18
-61.70
28
A
LYS
4
71.29
118.39
28
A
PRO
5
-74.98
-162.55
28
A
GLU
10
69.92
-57.20
28
A
ASP
11
-175.17
-83.55
28
A
ALA
12
63.48
154.86
28
A
ALA
14
42.57
26.31
29
A
SER
3
178.15
-71.27
29
A
ASP
6
177.24
-54.09
29
A
GLU
10
-123.58
-50.75
29
A
ARG
33
-132.90
-44.82
29
A
ARG
35
-91.01
32.15
30
A
SER
3
82.16
-64.31
30
A
GLU
10
-130.07
-55.26
30
A
ASP
11
48.37
94.66
30
A
ALA
12
174.06
165.43
30
A
ALA
14
83.75
-51.17
30
A
AIB
32
-170.71
-32.81
[ALA31, AIB32]-NEUROPEPTIDE Y
1
N
N
A
ASP
16
A
ASP
16
HELX_P
A
ASN
29
A
ASN
29
1
1
14
covale
1.348
both
A
ALA
31
A
C
ALA
31
1_555
A
AIB
32
A
N
AIB
32
1_555
covale
1.330
both
A
AIB
32
A
C
AIB
32
1_555
A
ARG
33
A
N
ARG
33
1_555
covale
1.325
both
A
TYR
36
A
C
TYR
36
1_555
A
NH2
37
A
N
NH2
37
1_555
HORMONE/GROWTH FACTOR
alpha, 310-helix, HORMONE-GROWTH FACTOR COMPLEX
NEUY_PIG
UNP
1
1
P01304
YPSKPDNPGEDAPAEDLARYYSALRHYINLITRQRY
1
36
1FVN
1
36
P01304
A
1
1
36
1
ILE
engineered mutation
ALA
31
1FVN
A
P01304
UNP
31
31
1
THR
engineered mutation
AIB
32
1FVN
A
P01304
UNP
32
32
BINDING SITE FOR RESIDUE NH2 A 37
A
NH2
37
Software
2
A
ARG
33
A
ARG
33
2
1_555
A
TYR
36
A
TYR
36
2
1_555
1
P 1